Indegene Limited, through its wholly owned subsidiary Indegene Healthcare UK Limited, has signed a Share Purchase Agreement (SPA) to acquire 100% equity shares in two UK-based companies: DT Associates Research and Consulting Services Limited ('DT UK') and Trilogy Writing and Consulting Limited ('Trilogy UK'). This acquisition was signed on March 01, 2026. DT UK, engaged in analytics, technology, and commercial, medical, regulatory, and safety services for life science and healthcare organizations, reported a revenue of GBP 6,400,711 in its last financial year. Trilogy UK, which provides writing and training services for the pharmaceutical industry, reported a revenue of GBP 2,340,488 in its last financial year. Both companies were incorporated in England and Wales, with DT UK incorporated on July 25, 2013, and Trilogy UK on January 19, 2011. The acquisition, considered an internal restructuring, involves a cash consideration of £2,001,000 for DT UK and £702,348 for Trilogy UK, totaling £2,703,348. Consequent to this acquisition, DT UK will cease to be a subsidiary of ILSL Holdings, Inc., and Trilogy UK will cease to be a subsidiary of Trilogy Writing and Consulting GmbH. Both entities will become wholly owned subsidiaries of Indegene Healthcare UK Limited. The acquisition is expected to be completed by March 31, 2026. The transactions fall within related party transactions, but no promoter or group companies have an interest in the entities being acquired, and the transactions are conducted on an arm's length basis. Indegene Limited has made this information available on its corporate website.
